TNF and melanoma: Specifically, it augmented the antitumor activity of TNF‐α and CDDP against Ehrlich ascites carcinoma and against melanoma B16 bearing mice.187 More importantly, treatment of mice with 33 at a dose as low as 0.05 μg/mouse decreased the toxicity of CDDP (40 μg/mouse)/TNF‐α (500 U/mouse) combination and normalized changes in hematological parameters (decreased lymphocytes, increased monocytes, and neutrophils) attributed to CDDP/TNF‐α treatment.187